Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
P-tau217 Test · 1 trial · 1 indication
Cognitive composite may consist of International Daily Symbol Substitution Test-Medicines (iDSSTm ), International Shopping List Test (ISLT), Continuous Paired Associate Learning Test (CPAL). Time to cognitive worsening is defined as a change in cognitive composite score or any of the individual composite components, from baseline at 2 consecutive visits.
| Arm | Type | Description |
|---|---|---|
| Elevated Plasma P-tau217 Levels | OTHER | Participants with known elevated plasma P-tau217 levels who are cognitively unimpaired at baseline per self-report. |
| Not-Elevated P-tau217 Levels | OTHER | Participants with known not-elevated plasma P-tau217 levels who are cognitively unimpaired at baseline per self-report. |
| Name | Type | Description |
|---|---|---|
| P-tau217 Test | OTHER | A plasma test measuring phosphorylated tau at Position 217 (P-tau217). |
Inclusion Criteria: * The participant must self-report unimpaired cognition. * The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening. Exclusion Criteria: * Have seen a doctor about memory concerns. * Have a history or diagnosi...
Top 20 of 24 competitors
The P-tau217 Test is a diagnostic biomarker test being studied for use in Alzheimer Disease. It is currently in Phase 3 clinical development as an investigational test. The test is being evaluated in a large epidemiology and biomarker study to assess its utility in the condition.
The P-tau217 Test targets phosphorylated tau at threonine 217, a specific form of tau protein associated with Alzheimer Disease pathology. This biomarker is measured to help identify or monitor the disease process. The test is being investigated for its diagnostic capabilities in Alzheimer Disease.
The P-tau217 Test is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting a Phase 3 clinical trial to evaluate the test's performance in Alzheimer Disease.
The P-tau217 Test is in Phase 3 clinical development. It is an investigational test and has not been approved by regulatory authorities. The ongoing Phase 3 trial is actively recruiting participants to evaluate the test in Alzheimer Disease.
The P-tau217 Test is being evaluated in a single Phase 3 clinical trial with the identifier NCT07142954, titled 'Epidemiology and Biomarker Study in Alzheimer's Disease'. This recruiting study plans to enroll 3,400 participants aged 55 years and older in the United States and Japan.